Centauri Therapeutics raises €3.5M Seed round
19 January 2016· Nether Alderley, United Kingdom· health, biotech, b2b, b2g, deep_hardware
The company intends to use the funds to develop its first lead Alphamers against anti-microbial resistant pathogens and to acquire the Alphamer technology for drug discovery and development from Altermune Technologies LLC.
“We are extremely pleased to welcome the AMR Action Fund as a new investor. Their dedication to advancing the field of antimicrobials further reinforces our belief in the Alphamer platform as a transformative immunotherapeutic approach for addressing infections. This latest investment has enabled us a clear path to progress CTX-187 beyond Phase I trials and onto the development of a Phase II-ready asset.”
Investors
LeadAnimatrix Capital LLP
About Centauri Therapeutics
Headquarters
Nether Alderley, United Kingdom
Founded
2014
Team Size
21–50
Sectors
healthbiotechb2bb2gdeep_hardware
Source: https://www.finsmes.com/2016/01/centauri-therapeutics-raises-3m-in-funding.html